- Ovarian Cancer Therapy: Homologous Recombination Deficiency as a Predictive Biomarker of Response to PARP Inhibitors.
- Miller RE, Elyashiv O, El-Shakankery KH, Ledermann JA.
- Onco Targets Ther. 2022 Oct 4;15:1105-1117. doi: 10.2147/OTT.S272199.
- PMID: 36217436
- PubMed abstract
- Review
- Free PMC article
- Free Full Text